Posted 19th January 2018 by Laura Berry
The human microbiome is an area of life sciences that is gaining traction in the venture capital community. According to the Wall Street Journal, venture capital investment in microbiome companies rose 458.5 percent to 114.5 million U.S. dollars during the period from 2011 – 2015.
Posted 11th January 2018 by Gaspar Taroncher-Oldenburg
Microbiome-based interventions, whether therapeutic or prophylactic, come in a broad spectrum of modalities, a consequence of the complexity of and possibilities afforded by the microbiome.
Posted 27th December 2017 by Laura Berry
Defined health outcomes are increasingly being linked to prebiotic ingredients and supplements. For example, mounting evidence recently led the FDA to issue a qualified health claim regarding the ability of digestion resistant starch to reduce the risk of type 2 diabetes. With the direct annual cost of diabetes recently estimated to be $825B (1), the potential application of prebiotics to reduce disease risk is appealing from both health care and business investment perspectives.
Posted 18th December 2017 by Laura Berry
2017 has been another big year for microbiome research. Not only is funding at an all-time high but the shift from 16S to whole-genome sequencing means that we are able to deduce the role it plays in health more effectively.
Posted 14th December 2017 by Gaspar Taroncher-Oldenburg
“The two reports chart the ecological landscape of microbiome methods ‘in the wild’ and should engender a newfound sense of urgency to optimize methods and to improve reproducibility between laboratories.”
Posted 8th December 2017 by Kate Barlow
There is a Second Green Revolution underway that is harnessing precision agriculture, no-till farming practices, biological, rather than chemical crop inputs and other new, innovative tools that improve soil health and water quality.
Posted 6th December 2017 by Laura Berry
The current healthcare climate is on the brink of a long overdue makeover. The clinical research industry has been increasingly plagued by a resistance to change and is subsequently feeling the pain of this reluctance to modify its approach. Indicative of this trend are the rising prices of drug and medical device development, declining patient retention and adherence in clinical research, mounting administrative burdens, and exponentially growing expenses for clinical research that are unsustainable.
Posted 27th November 2017 by Laura Berry
The human skin is densely colonised with a complex microbial community (1). Microbes are a part of the skin barrier that, combined with innate immunity, keeps the balance essential to maintaining healthy skin (2). Recent and independent research projects strongly suggested that human skin microbiota is of a major importance for human health and could be targeted to improve the skin health.